Drug Eluting Stent (DES) Market 21.2 CAGR Growth Outlook 2024-2030

Key Insights

The Drug Eluting Stent (DES) Market size was valued at USD 5.71 USD billion in 2023 and is projected to reach USD 21.94 USD billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. Drug-eluting stents (DES) are small small, wimpy mesh tubes used to treat arteries that do not pass on the blood effectively. The stent is drug coated with the drugs that are slowly released into the artery wall, lowering inflammation and preparing the artery to not close with the stent. DES is stable in a manner through the process called PCI that widens the arteries to allow the flow of blood, and therefore, reduces the possibility of heart attack. The DES cardiovascular market is made up of the increasing prevalence of coronary artery disease and the emerging need for minimally invasive procedures that place transcatheter implants. At the sideline of the recent state era and drug delivery systems development, the DES gave birth to the marketplace expected to be a constantly growing supply platform of more developed treatment alternatives for coronary patients. There is a significant improvement over the bare metal kind with the drug-eluting stents which enables the continued expansion of arteries and reduces the need for repeat procedures while the long-term cardiovascular health is enhanced.

Drug Eluting Stent (DES) Trends

• Growing adoption of DES in peripheral vascular interventions
• Advancements in stent design and materials
• Development of biodegradable and resorbable stents

Driving Forces: What's Propelling the Drug-Eluting Stent (DES) Market

• Rising Prevalence of Cardiovascular Diseases: Increasing incidence of conditions such as coronary artery disease and peripheral artery disease is driving demand for DES.
• Technological Advancements: Development of stents with improved biocompatibility, reduced thrombosis risk, and enhanced drug delivery systems.
• Government Initiatives: Support for research and development, along with reimbursement policies, is encouraging the adoption of DES.
• Aging Population: The increasing number of elderly individuals with cardiovascular risks is expanding the target market.

Challenges and Restraints in the Drug-Eluting Stent (DES) Market

• Cost Concerns: The high cost of DES can limit accessibility in certain regions.
• Safety Issues: Rare cases of late thrombosis and stent failure can hinder market growth.
• Competition from Bare-Metal Stents: Despite lower costs, bare-metal stents still hold a significant market share.

Emerging Trends in Drug Eluting Stent (DES)

• Bioresorbable Stents: Development of stents that dissolve over time, reducing the need for long-term follow-up.
• Personalized Medicine: Tailoring DES therapy based on patient-specific factors to improve outcomes.
• Artificial Intelligence (AI): Integration of AI in stent design and procedural planning to optimize treatment efficacy.

Growth Catalysts in the Drug-Eluting Stent (DES) Industry

• Technological Advancements in Drug Delivery: Improved nanoparticle-based drug delivery systems, such as micelles and liposomes.
• Collaboration between Medical Device and Pharmaceutical Companies: Partnerships to develop innovative DES with tailored drug formulations.
• Expansion into Emerging Markets: Growing healthcare infrastructure and increasing disposable income in developing countries present significant opportunities.

Market Segmentation: Drug Eluting Stent (DES) Analysis

Type:

• Coronary Stenting
• Peripheral Stenting

Scaffold:

• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others

Drug:

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Others

End User:

• Hospitals
• Specialty Clinics

Leading Players in the Drug-Eluting Stent (DES) Market

• Boston Scientific Corporation
• Abbott
• Medtronic
• Biotronik
• Terumo Corporation
• MicroPort Scientific Corporation
• Sahajanand Medical Technologies
• B. Braun SE
• Lepu Medical Technology(Beijing)Co.,Ltd.
• Cook

Significant developments in the Drug-Eluting Stent (DES) Sector

• Boston Scientific's launch of the SYNERGY DES system with a bioresorbable polymer coating.
• Abbott's acquisition of Evalve, Inc. to expand its transcatheter aortic valve replacement (TAVR) offerings.
• Medtronic's development of the Resolute Onyx DES with a durable polymer coating for improved stent expansion.

Comprehensive Coverage Drug Eluting Stent (DES) Market Report

Regional Insight:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

DROCT:

• Drivers
• Restraints
• Opportunities
• Challenges
• Threats

Pricing Analysis:

• Historical pricing trends
• Current pricing analysis
• Future pricing forecasts

Import And Export Analysis:

• Major import and export countries
• Trends in import and export volumes
• Impact on market dynamics

Segmentation:

• Regional segmentation
• Type Segmentation
• Scaffold segmentation
• Drug segmentation
• End-user segmentation

Patent/Trademark Analysis:

• Key patents and trademarks
• Analysis of the intellectual property landscape
• Impact on market competition